Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457
Peer-review started: April 18, 2018
First decision: April 27, 2018
Revised: May 6, 2018
Accepted: May 18, 2018
Article in press: May 18, 2018
Published online: June 21, 2018
Core tip: Vedolizumab represents an interesting new therapeutic option for the treatment of patients with moderate-to-severe ulcerative colitis and Crohn’s disease that are refractory or intolerant to either conventional treatments or anti-TNFα agents. This review describes the efficacy, safety, and tolerability of vedolizumab demonstrated in the clinical GEMINI trials. In addition, the paper reviews the effectiveness and the safety of vedolizumab in the real-world studies in order to identify its place in treatment algorithms for patients with inflammatory bowel disease.